Introduction
Medical Oncology Grand Rounds begin each year after completion of the Friday Introduction to Cancer Management lectures. Fellows and faculty members give 30- to 60-minute, case-based discussions and literature reviews on subjects of their choosing.
Schedule
- Friday, Noon-1:00 PM
- 11th Floor Mid Campus Center, Main Conference Room (in person)
- Zoom (virtual)
Note: Beginning in July, 2016, Hematology Grand Rounds and Medical Oncology Grand Rounds have been held separately.
Academic year
| Date | Speaker | Title |
|---|---|---|
| Jul 7, 2023 | Michael Kramer | Nucleophosmin Mutations in AML: From the Cell to the Patient |
| Sep 8, 2023 | Nathan Singh | Detangling CAR-driven T-cell dysfunction |
| Sep 15, 2023 | Joshua Mitchell | Treating the Cancer While Safeguarding the Heart: Seeking Balance from Prevention through Survivorship |
| Sep 22, 2023 | Amanda Cashen | Human Subjects Research in Oncology: Lessons from a Former IRB Executive Chair |
| Sep 29, 2023 | Neha Mehta-Shah | Taking Steps Towards Progress in Peripheral T-cell Lymphoma |
| Oct 6, 2023 | Piro Lito | Emerging KRAS Directed Therapeutics: Implications for Cancer Biology and Therapy |
| Oct 13, 2023 | Max Wattenberg | Programming the Myeloid Response for Cancer Immunotherapy |
| Oct 20, 2023 | Michael Slade | The Goldilocks Principle: Moving Toward Personalized Maintenance in Multiple Myeloma |
| Oct 27, 2023 | Ron Germain | Using Advanced Multiplex Microscopy and Computational Tools to Analyze Immune Responses in Normal and Malignant Tissues |
| Nov 17, 2023 | Chris Counter | RAS mutation tropism -why specific RAS mutations track with specific cancers |
| Dec 1, 2023 | Bob Maki | Ewing Sarcoma: 100+ years of clinical and scientific progress |
| Dec 15, 2023 | Brian Van Tine | Translating Arginine Deprivation with PEGylated Arginine Deiminase (ADI-PEG 20) in Sarcoma and Other Cancers |
| Jan 5, 2024 | Nathan Singh | Detangling CAR-driven T-cell dysfunction |
| Jan 12, 2024 | CANCELED | |
| Jan 19, 2024 | Imran Nizamuddin | Moving the Goalpost in Post-Transplant Lymphoproliferative Disorders: Current Treatments and Future Directions |
| Jan 26, 2024 | Funda Meric-Bernstam | |
| Feb 2, 2024 | Ramon Jin | |
| Feb 9, 2024 | Greg Longmore | Tumour-Environmental Interactions Regulating Cancer Progression |
| Feb 16, 2024 | Emily Podany | Biomarker-Directed Neoadjuvant Treatment Decisions in HR+/HER2- Breast Cancer and Impacts on Equity |
| Feb 23, 2024 | Russel Pachynski | Improving Cellular Therapy and Diagnosis for Metastatic Prostate Cancer Patients |
| Mar 1, 2024 | Giulia Petrone | The Landscape of Clonal Hematopoiesis in the Era of Precision Medicine |
| Mar 8, 2024 | Patricia LoRusso | Optimal Dose Determination in Phase I Clinical Trials |
| Mar 15, 2024 | Wilbur Song | Pearls & Pitfalls of Targeting Tumor Antigens |
| Mar 22, 2024 | Constantine Logothetis | Inflammation in MDS and VEXAS Syndrome: Does One Size Fit All |
| Mar 29, 2024 | Brendan Knapp | Improving Survival in Unresectable Stage II Non-Small Cell Lung Cancer: Moving Beyond PACIFIC |
| Apr 5, 2024 | Michael Iglesia | Cancer Multiomics: Applications and Updates |
| Apr 12, 2024 | Margaret Ship | Genetic Heterogeneity and Rational Treatment Targets in Lymphoid Malignancies |
| Apr 19, 2024 | Miriam Kim | |
| Apr 26, 2024 | Nicole Foley | |
| May 3, 2024 | Jesse Zaretsky | |
| May 10, 2024 | Tanner Johanns | |
| May 17, 2024 | Michael Kramer | |
| May 24, 2024 | Nikolaos Trikalinos | |
| May 31, 2024 | Gio Cittolin Santos | |
| Jun 14, 2024 | Doug Adkins | |
| Jun 21, 2024 | Michael Bern | |
| Jun 28, 2024 | Christine Auberle |
| Date | Speaker | Title |
|---|---|---|
| Sep 16, 2022 | Andrew Chow | Mobilizing the Full Immunological Armamentarium in Lung Cancer |
| Sep 23, 2022 | Jeffrey Aldrich | Highlights From Research in Supportive Care and Outcome Disparities in Breast Cancer |
| Oct 14, 2022 EPNEC Seminar Room A | Trever Bivona, MD, PhD University of California San Francisco | Emerging Insights Into Oncogenic RTK-RAS Signaling |
| Oct 28, 2022 | Stefan Tarnawsky | Update to the Prognostication and Classification of Myelodysplastic Syndromes |
| Nov 4, 2022 | Mohammad Atiq, MD National Institutes of Health | Exploring Immunocytokine Synergy With Chemotherapy in Metastatic Prostate Cancer |
| Nov 11, 2022 | Katherine Weilbaecher | Breast Cancer Metastasis in Bone: Insights Into Old Therapies and New Approaches |
| Dec 16, 2022 | Maria B. Magella Doyle, MD Department of Surgery | Transplant Oncology – Making New Strides in Cancer Care |
| Jan 6, 2023 | Brad Kahl | Mantle Cell Lymphoma – What Did We Learn in 2022? |
| Jan 13, 2023 | Arvind Ravi, MD, PhD Dana-Farber Cancer Institute | Integrative Approaches to Understanding Therapeutic Response and Resistance |
| Jan 20, 2023 | Thomas Westbrook, MD University of Michigan | Lineage Plasticity in Prostate Cancer: Mechanistic Insight and Therapeutic Implications |
| Jan 27, 2023 | David Russler-Germain | Follicular Lymphoma: New Insights, Treatments, and Opportunities |
| Feb 3, 2023 | Kelly Bolton | Germline Genetic Predisposition to Cancer: Paradigm Shifts and Practical Application in Oncology Care |
| Feb 10, 2023 | Raya Saba | Management of Diffuse Large B-Cell Lymphoma in Older Patients |
| Feb 17, 2023 | Ron Bose | Trastuzumab Deruxtecan in Breast, Lung, and Gastroesophageal Cancers |
| Feb 24, 2023 | Fahrettin Covut | CAR T-Cell and Bispecific Therapies for Relapsed Refractory Multiple Myeloma |
| Mar 3, 2023 | Kian-Huat Lim | Targeting Tumor Innate Inflammation in GI Cancers |
| Mar 10, 2023 | Christopher Maher | Altered Noncoding Regulation Across Solid Tumors |
| Mar 17, 2023 | Priyanka Verma | Targeting Base Damage Repair to Overcome Limitations of PARP Inhibitor Thaerapy in BRCA-Mutant Cancers |
| Mar 24, 2023 Holden Auditorium | Norman “Ned” Sharpless, MD University of North Carolina | Ending Cancer as We Know It: Forecasting Future Cancer Progress |
| Mar 31, 2023 | Akash Patnaik, MD, PhD, MMSc University of Chicago | Activating Innate Immunity in Prostate Cancer: From Bedside to Bench and Back |
| Apr 7, 2023 | Bindiya Patel | Targeting MET in NSCLC |
| Apr 14, 2023 | Andrew Young | Understanding Cancer Risk in Firefighters |
| Apr 21, 2023 | Jonathan Trujillo, MD, PhD University of Chicago | The Role of Cancer Cell-Intrinsic Hypoxia Inducible Factor (HIF) Activation in Tumor Immune Evasion |
| Apr 28, 2023 | Danielle Atibalentja, MD, PhD Stanford University | Deciphering B-Cell Responses in a Pre-Clinical Model of MYC-Driven T-Cell Lymphoma |
| May 5, 2023 | Chongj-Xian Pan, MD, PhD Brigham and Women’s Hospital, Harvard Medical School | Translational Research to Address Unmet Needs in Bladder Cancer |
| May 12, 2023 | Jill Phallen, PhD Johns Hopkins School of Medicine | Liquid Biopsy Approaches and Cell-Free DNA Biology for Early Detection of Cancer |
| May 19, 2023 | Matthew Christopher | Improving the Graft-Versus-AML Effect |
| May 26, 2023 | Jared Cohen | Advances in the Diagnosis and Treatment of Lymphatic Dysgenesis and the Emerging Role of the Medical Oncologist |
| Jun 9, 2023 | Andrea Hagemann, MD Department of Obstetrics & Gynecology | Prioritizing Gynecologic Cancer Prevention: Panel Testing, Preventive Surgeries, and More |
| Jun 16, 2023 | Nicole Foley | Personalizing Therapy for Patients With T-Cell Lymphomas |
| Jun 23, 2023 | Giordano Cittolin-Santos | Small Cell Lung Cancer: Changes in Epidemiology and Recent Advances |
| Jun 30, 2023 | Michael Iglesia Jesse Zaretsky | Liver Metastasis: Seed and Soil Checkpoint Immunotherapy, Beyond Anti-PD1 and CTLA4 |
| Date | Speaker | Title |
|---|---|---|
| Sep 24, 2021 | Whitney Hensing | Targeting HER2 in Breast Cancer: New Drugs and Paradigms |
| Oct 8, 2021 | Rigoberto Pizarro Fahrettin Covut | Overview of Health Disparities in Cancer Minimal Residual Disease in Multiple Myeloma |
| Oct 15, 2021 | Raya Saba Andrew Young | Updates in Frontline Treatment of Chronic Lymphocytic Leukemia Liquid Biopsy for Cancer Screening |
| Oct 22, 2021 | Eric Schwartz | Financial Burdens Surrounding Oral Cancer Therapy |
| Oct 29, 2021 | Patricia Ribeiro Pereira | Non-Invasive Nuclear Imaging of Cancer Biology to Convert Non-Responders Into Responders |
| Nov 5, 2021 | Melissa Reimers | Updates and Recent Advances in Renal Cell Carcinoma |
| Nov 12, 2021 | Daniel Link | Clonal Hematopoiesis: Etiology and Evolution |
| Nov 19, 2021 | Armin Ghobadi | Cellular Therapies for Cancer – A Primer and an Update |
| Nov 26, 2021 | Canceled – Holiday | |
| Dec 3, 2021 | Canceled – ASH Meeting | |
| Dec 10, 2021 | Canceled – ASH Meeting | |
| Dec 17, 2021 | Canceled | |
| Dec 24, 2021 | Canceled – Holiday | |
| Dec 31, 2021 | Canceled – Holiday | |
| Jan 7, 2022 | Patrick White | Innovative Tools and Strategies for Enhancing Support for Your Oncology Patients and Caregivers |
| Jan 14, 2022 | Canceled | |
| Jan 21, 2022 | Matthew Walter | Clonal Evolution of Myelodysplastic Syndromes |
| Jan 28, 2022 | Srivatsan Raghavan | The Tumor Microenvironment Drives Cell State, Plasticity, and Drug Response in Pancreatic Cancer |
| Feb 4, 2022 | Sheila Stewart | Age-Related Stromal Changes Drive Tumor Progression |
| Feb 11, 2022 | Giordano Cittolin-Santos Jared Cohen | Neoadjuvant Immunotherapy in NSCLC The Changing Landscape of Treatment in DLBCL |
| Feb 18, 2022 | Ravi Vij | Multiple Myeloma: The Best Is Yet to Come! |
| Feb 25, 2022 | Joshua Rubin | Adapting Cancer Treatment to Sex Differences in Cancer Biology |
| Mar 4, 2022 | Jason Weber | Identification of Drivers and Vulnerabilities in Breast Cancer |
| Mar 11, 2022 | Jing Wu | Translational Research in Developing a CDK9 Inhibitor Towards a Glioma Treatment |
| Mar 18, 2022 | Canceled | |
| Mar 25, 2022 | Bindiya Patel Michael Kramer | Biomarkers to Guide Adjuvant Therapy in Early-Stage NSCLC The Proteomic and Phosphoproteomic Landscapes of Acute Myeloid Leukemia |
| Apr 1, 2022 | Joseph Franses Massachusetts General Hospital | Identifying and Targeting Metastatic and Microenvironmental Drivers in Hepatocellular Carcinoma |
| Apr 8, 2022 | Todd Fehniger | Activate and Recollect: Training Natural Killer Cells for Cancer Immunotherapy |
| Apr 15, 2022 | Jing Xi | A Silent Epidemic? – Disparities in Breast Cancer for Sexual and Gender Minority Women |
| Apr 22, 2022 | Miriam Jacobs | Applications of Memory-Like Natural Killer Cells for Head and Neck Cancer Immunotherapy |
| Apr 29, 2022 | Michael Gillette Broad Institute, Cambridge, MA | Deep Integrated Proteogenomics Reveals New Biology and Therapeutic Vulnerabilities in Non-Small Cell Lung Cancer |
| May 6, 2022 | Foluso Ademuyiwa and Mark Fiala | Racial Disparities in Oncology: Challenges and Opportunities |
| May 13, 2022 | Michael Iglesia | Metastasis in Colorectal Cancer |
| May 20, 2022 | Milan Chheda | Tuning In: A Review of Psychedelics for Patients With Cancer |
| May 27, 2022 | Nicole Foley Michael Slade | T-Cell Lymphomas and HSCT Why CARs Crash: CAR T Cell Treatment Failure and the PD-1/PD-L1 Axis |
| Jun 3, 2022 | Canceled – ASCO Meeting | |
| Jun 10, 2022 | Timothy Ley | AML Proteomics and Interactomics |
| Jun 17, 2022 | Omar Butt | The Intersection of the Blood Brain Barrier, Neuro-Inflammation, and Neuro-Degeneration in Neuro-Oncology |
| Jun 24, 2022 | Charles Swanton Francis Crick Institute, London, UK | PAUL CALABRESI K12 VISITING PROFESSOR Lung Cancer Evolution, Metastases and Immune Evasion: Insights From TRACERx |
| Date | Speaker | Title |
|---|---|---|
| Sep 18, 2020 | Grant Challen | The Epigenetic Regulation of Hematopoietic Stem Cells: From Clonal Hematopoiesis to Myeloid Neoplasia |
| Sep 25, 2020 | Malachi Griffith | Immunogenomics Approaches to Identify and Characterize Neoantigens |
| Oct 9, 2020 | Andrew Young | Clonal Hematopoiesis of Indeterminate and Determinate Potential |
| Oct 16, 2020 | Vanessa Eulo | Advancing Therapies in Sarcoma |
| Oct 30, 2020 | Stephanie Perkins Radiation Oncology Brian Baumann Radiation Oncology | The Role of Proton Therapy in Adult Cancers The Promise of Proton Therapy as Part of Concurrent Chemo-Radiotherapy |
| Nov 6, 2020 | Sid Devarakonda | Implications of Cancer-“omics” Studies for Clinical Practice |
| Nov 13, 2020 | Ryan Fields Department of Surgery | The Clonal Evolution of Metastatic Colon Cancer: Insights and Implications for Patient Care |
| Dec 11, 2020 | Ian Hu, MD, PhD National Cancer Institute | Translational Research at NCI |
| Dec 18, 2020 | Michael Slade Michael Iglesia | Assessing Allogeneic Transplant Eligibility in Older Adults Breast Cancer Subtypes at the Single-Cell Level: Results From the Human Tumor Atlas Network |
| Jan 8, 2021 | Sanjeev Bhalla Department of Radiology | Chest Imaging for the Oncologist |
| Jan 15, 2021 | Fahrettin Covut David Russler-Germain | Advances in Multiple Myeloma Treatment Integrating Genomics Into Lymphoma Treatment Strategies |
| Jan 22, 2021 | Michael Deininger, MD, PhD Huntsman Cancer Institute, University of Utah | A Critical Role for SIRT5 in Acute Myeloid Leukemia Metabolism |
| Jan 29, 2021 | Brian Miller, MD, PhD Harvard Medical School, Dana Farber Cancer Institute | Defining Immune Mechanisms to Overcome Resistance to Immunotherapy |
| Feb 5, 2021 | Amir Iravani Department of Radiology | Molecular Imaging of Cancer and Immune Response to Immunotherapy |
| Feb 12, 2021 | David S. Hong, MD MD Anderson Cancer Center | Cracking Open the Undruggable RAS |
| Feb 19, 2021 | Steven P. Treon, MD, PhD Dana-Farber Cancer Institute | Treatment Advances in Waldenstrom’s Macroglobulinemia |
| Feb 26, 2021 | Whitney Hensing Raya Saba | Targeting HER2 Mutations in Cancer Overview and Advances in Treatment of Mantle Cell Lymphoma |
| Mar 5, 2021 | Priyanka Verma, PhD University of Pennsylvania | Chromatin Accessibility: A New Vulnerability in BRCA-Mutant Cancers |
| Mar 12, 2021 | Dhruv Bansal | Discovering an Immunologic Beachhead in the Prostate Tumor Microenvironment |
| Mar 19, 2021 | Elizabeth M. Jaffee, MD Johns Hopkins University | Pancreatic Cancer Is PRIMED to Become an Immunologic Disease |
| Mar 26, 2021 | Barbara Burtness, MD Yale School of Medicine | The Emerging Therapeutic Landscape in Head and Neck Cancer |
| Apr 2, 2021 | Lindsay Peterson | Precision Nutrition in Cancer Care |
| Apr 9, 2021 | Zahra Kabiri, MD, PhD Duke University | Interrogating the Role of Ras and Wnt Signaling Intensity in Colorectal Cancer |
| Apr 16, 2021 | Robert Orlowski, MD, PhD MD Anderson Cancer Center | Novel Antibody Drug Conjugates for Hematologic Malignancies |
| Apr 23, 2021 | Miriam Jacobs | The Role of Natural Killer Cells in Solid Tumor Immunotherapy |
| Apr 30, 2021 | Ramon Jin | The Role of SOX2 in Barrett’s Esophagus and Esophageal Adenocarcinoma |
| May 7, 2021 | Gradon Nielsen | Impact of COVID on the Quality of Cancer Care Delivery |
| May 14, 2021 | Jing Xi | The Emerging Therapeutic Landscape in Breast Cancer With Brain Metastases |
| May 21, 2021 | Christian Grommes, MD Memorial Sloan Kettering Cancer Center | Primary CNS Lymphoma: Current Concepts and Changing Therapeutic Perspectives |
| May 28, 2021 | Zachary Crees Alice Zhou | The GENESIS Trial – CXCR4 Inhibition With Motaxafortide + G-CSF for Hematopoietic Stem Cell Mobilization in Multiple Myeloma Multiple Myeloma and the Tumor Microenvironment: Focus on NK Cells and Therapeutic Exploitation |
| Jun 11, 2021 | Carmen Bergom, MD, PhD Radiation Oncology | Un-Break My Heart: Using Pre-Clinical and Clinical Data to Minimize Radiation-Induced Heart Dysfunction |
| Jun 18, 2021 | Michael Kramer | Machine Learning for the Oncologist: How the Machines Can Help You Help Patients |
| Jun 25, 2021 | Kelsey S. Lau-Min, MD University of Pennsylvania | Bridging the Evidence-To-Practice Gap in Cancer Care: The Precision Oncology Experience |
| Jul 2, 2021 | Ryan Day | Core-Binding Factor Leukemias: Mechanism and Treatment |
| Date | Speaker | Title |
|---|---|---|
| Aug 9, 2019 | Mark E. Burkard, MD, PhD University of Wisconsin School of Medicine & Public Health, Madison, WI | Enhancing Precision of Breast Cancer Treatment |
| Aug 16, 2019 | Trudy G. Oliver, PhD University of Utah, Salt Lake City, UT | MYC Drives a Unique Metabolic and Therapeutically-Relevant Subset of Small Cell Lung Cancer |
| Sep 13, 2019 | Patrick Grierson | The MK2/Hsp27 Axis as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma |
| Sep 20, 2019 | Julien Sage, PhD Stanford University, Stanford, CA | Mechanisms of Small Cell Lung Cancer Metastasis |
| Sep 27, 2019 | Ramon Jin | Organoids to Study Upper GI Malignancies |
| Oct 4, 2019 | Shivani Ahlawat, MD Johns Hopkins University, Baltimore, MD | Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Tumors – What Is the State of the Art Imaging? |
| Oct 18, 2019 | Gradon Nielsen Alice Zhou | High Value Cancer Care Immunosuppression and Tumorigenesis: Lessons From Cyclosporine A on Angiogenesis |
| Oct 25, 2019 | Keith Stewart, MB, ChB, MBA Mayo Clinic, Rochester, MN | HARVEY & LINDA SALIGMAN LECTURE Multiple Myeloma: Advances in Diagnostics and Care |
| Nov 1, 2019 | Sarat Chandarlapaty, MD, PhD Memorial Sloan Kettering Cancer Center, New York, NY | Breast Cancer Resistance to Combination Endocrine Therapy: Mechanisms and Therapeutic Implications |
| Nov 22, 2019 | Mary-Kate Malecek Zachary Crees | Targeting the PI3K Pathway in Cancer Bone Marrow Niche – Hematopoietic Stem Cell (HSC) Signaling and Therapeutic Implications for Peripheral Blood (PB) HSC Mobilization |
| Dec 13, 2019 | John L. Hays, MD, PhD Ohio State University, Columbus, OH | Finding the Right Targets in Recurrent Ovarian Cancer |
| Dec 20, 2019 | Daniel J. Lenihan, MD Cardiovascular Division | Cardio-Oncology: A New Part of the Team |
| Jan 10, 2020 | Ryan Day Daniel Guy | Maintenance Therapy in AML/MDS Blastic Plasmacytoid Dendritic Cell Neoplasm |
| Jan 17, 2020 | Aadel Chaudhuri Radiation Oncology | Cell Free DNA Liquid Biopsy: Tumor Surveillance, Risk Stratification and MRD Detection |
| Jan 24, 2020 | George Souroullas | Understanding the Role of EZH2 Mutations on Chromatin Dynamics and Oncogenesis |
| Jan 31, 2020 | Brett Herzog | Modeling Stromal-Induced Immunotherapy Resistance in Lung Cancer |
| Feb 7, 2020 | Jason Held | Cancer Biochemistry Through the Lens of Chemical and Redox Biology |
| Feb 14, 2020 | Francesca Ferraro | Measurable Residual Disease (MRD) in AML: Challenges and Opportunities for Intervention |
| Feb 21, 2020 | Alessandro Vindigni | Mechanisms of DNA Replication Stress Response to Chemotherapeutics |
| Feb 28, 2020 | Mia Weiss, MD Rush University Medical Center, Chicago, IL | Treatment of Metastatic Soft Tissue Sarcoma in the Era of Next Generation Sequencing |
| Mar 6, 2020 | Derek A. Wainwright, PhD Northwestern University, Chicago, IL | Improving Survival by Reversing the Effects of Aging in Patients With Glioblastoma |
| Mar 13, 2020 | Conference suspended until May 1 due to COVID-19 | |
| May 1, 2020 | Lauren Shea Jing Xi | Treatment of PTLD: Current Approaches and Emerging Therapies Emerging Novel Therapies for HER2-Positive Metastatic Breast Cancer |
| May 15, 2020 | Bruna Pellini Ferreira | Urinary Cell-Free DNA Analysis for Tumor Mutation Detection in Patients With Oligometastatic Colorectal Cancer |
| May 29, 2020 | Haeseong Park | COVID-19 and Cancer |
| Jun 5, 2020 | Stephen Sykes, PhD Fox Chase Cancer Center, Philadelphia, PA | The Role and Regulation of Serine Metabolism in Acute Myeloid Leukemia |
| Jun 12, 2020 | Michael Iglesia Miriam Jacobs | Predicting Response to Immunotherapy: PD-L1 and Beyond The Role of IL-15 as a Cancer Immunotherapy |
| Jun 19, 2020 | Whitney Hensing David Russler-Germain | Immunotherapy in TNBC: Advances in Early Stage Disease Bispecific Antibodies in Lymphoid Malignancies: Past, Present, and Future |
| Date | Speaker | Title |
|---|---|---|
| Sep 7, 2018 | Melissa A. Reimers, MD University of Michigan, Ann Arbor, MI | Precision Medicine and Immunotherapy in Metastatic Prostate Cancer |
| Sep 14, 2018 | Jonathan R. Strosberg, MD Moffitt Cancer Center, Tampa, FL | Overview of Treatments for Metastatic Gastroenteropancreatic Neuroendocrine Tumors |
| Sep 28, 2018 | Matthew J. Ellis, MD, PhD Baylor College of Medicine, Houston, TX | Breast Cancer Proteogenomics |
| Oct 5, 2018 | Benjamin Tan | Localized Rectal Cancer: Navigating Shifting Paradigms |
| Oct 12, 2018 | Aabha Oza | Management of Advanced Renal Cell Carcinoma |
| Oct 19, 2018 | Armin Ghobadi | CAR-T Cell Therapy and Its Complications |
| Oct 26, 2018 | Nabil M. Ahmed, MD, MPH Baylor College of Medicine, Houston, TX | A Homing System Targets Therapeutic T Cells to Brain Cancer |
| Nov 2, 2018 | Kenneth C. Anderson, MD Dana-Farber Cancer Institute, Boston, MA | Novel Therapeutic Strategies in Multiple Myeloma |
| Nov 9, 2018 | Nkiruka Ezenwajiaku Ramon Jin | Molecular Classification of Triple Negative Breast Cancer GI Organoids in Cancer Research |
| Dec 7, 2018 | Amber Xu | Target Therapy in Non-Small Cell Lung Cancer |
| Dec 14, 2018 | Milan Chheda | Using Zika Virus to Target Glioblastoma Stem Cells |
| Jan 4, 2019 | Kristen Sanfilippo | Cancer Associated Thrombosis: Prevention to Treatment |
| Jan 11, 2019 | Brett Herzog Ramzi Abboud | Fibrosis Modulates Lung Cancer Immunity and Progression Invariant NKT Cells: Harnessing Their Immunoregulatory and Effector Functions |
| Jan 18, 2019 | David DeNardo | Targeting the Pancreas Cancer Tumor Microenvironment to Improve Response to Immunotherapy |
| Jan 25, 2019 | Gradon Nielsen Lauren Shea | Economic Challenges in Modern Oncology and the Need for Innovation Treatment of Brain Metastases in Non-Small Cell Lung Cancer |
| Feb 1, 2019 | Kian Lim | Targeting the Innate Immune Inflammatory Pathway in Pancreatic Cancer |
| Feb 8, 2019 | Bruna Pellini Ferreira Daniel Guy | Urinary cfDNA in Lung Cancer Surveillance: Present and Future Directions Bispecific Antibodies for Treatment of AML |
| Feb 15, 2019 | Meagan Jacoby | Can Measurable Residual Disease Monitoring Post-Transplant Improve Outcomes for MDS Patients? |
| Feb 22, 2019 | James Hsieh | Clinical and Translational Kidney Cancer Research: Now & Future |
| Mar 1, 2019 | Katherine Clifton, MD MD Anderson Cancer Center, Houston, TX | Exploring Oral Therapy Options in Geriatric Oncology: Analysis of Toxicity and Efficacy Of CDK4/6 Inhibitors in Metastatic Breast Cancer |
| Mar 15, 2019 | Sunyoung Lee, MD, PhD Roswell Park Comprehensive Cancer Center, Buffalo, NY | Immune Profiling and Prognostication of Lung and Pancreatic Adenocarcinoma |
| Mar 22, 2019 | Karin Hickey, MD Division of Endocrinology, Metabolism & Lipid Research | Endocrine Disorders in Cancer Patients |
| Mar 29, 2019 | Angela Hirbe | Clinical Challenges in the Diagnosis and Management of Neurofibromatosis-associated MPNSTs |
| Apr 5, 2019 | John Welch | Integrating Next-Generation Sequencing Into AML and MDS Clinical Trials |
| Apr 19, 2019 | Matthew Christopher | AML and the Graft-Versus-Leukemia Effect |
| Apr 26, 2019 | Vanessa Eulo Scott Goldsmith | Immunotherapy in Advanced Sarcoma Unfolding the Unfolded Protein Response: Implications for Cancer Therapy |
| May 3, 2019 | Charles Kaufman | Epigenetic Regulators of Melanoma Initiation |
| May 10, 2019 | David Spencer | Understanding Aberrent DNA Methylation in Leukemia |
| May 17, 2019 | Tanner Johanns | Neoantigens as Therapeutic Targets in Glioblastoma |
| May 24, 2019 | Ryan Day Mary-Kate Malecek | Targeting Apoptosis in AML Novel Therapies in Primary CNS Lymphoma |
| Jun 7, 2019 | Amber Afzal Miriam Jacobs | CDK9 Inhibition in Acute Myeloid Leukemia Use of Cytokine Induced Memory Like NK Cells for Relapsed Refractory AML |
| Jun 14, 2019 | Michael Green, MD MD Anderson Cancer Center, Houston, TX | Epigenetic Targeting of B-Cell Lymphoma |
| Jun 21, 2019 | Obi Griffith | Surveying the Genomic Landscape of Tumors and Tumor Models – The Next Frontier |
| Jun 28, 2019 | Gerald P. Linette, MD, PhD University of Pennsylvania, Philadelphia, PA | Immunological Ignorance of Solid Tumors |
| Date | Speaker | Title |
|---|---|---|
| Aug 25, 2017 | Nusayba Bagegni | Overcoming Drug Resistance in HER2+ Breast Cancer |
| Sep 1, 2017 | Ravi Vij | MM: AK47 or M24 |
| Sep 15, 2017 | Natasha Edwin | Physician Immigration and the US |
| Sep 22, 2017 | Jeffrey S. Miller, MD University of Minnesota | Novel Ways to Activate NK Cells to Treat Cancer |
| Sep 29, 2017 | Emily Jungheim, MD, MSCI Obstetrics and Gynecology | Fertility Preservation in 2017 at Washington University |
| Oct 6, 2017 | Brad Kahl | Mantle Cell Lymphoma: The State of the State |
| Oct 13, 2017 | Craig H. Moskowitz, MD Memorial Sloan Kettering Cancer Center | Hodgkin Lymphoma in the Near Future: Impact of Modern Nuclear Medicine, Radiotherapy, Brentuximab Vedotin and the Checkpoint Inhibitors |
| Oct 20, 2017 | Miriam Jacobs Ramon Jin | Immunotherapy in Metastatic Squamous Cell Head and Neck Cancer Cancer Stem Cells in Solid Tumors |
| Oct 27, 2017 | Bita Fakhri | Current and Emerging Treatment Strategies for Relapsed and Refractory Multiple Myeloma |
| Nov 3, 2017 | Ron Bose | Her2 Activating Mutations and the Challenge of Variants of Unknown Significance (VUS) in Breast Cancer Patients |
| Nov 10, 2017 | Daniel J. Lenihan, MD Cardiovascular Division | Cardio Oncology: How Can We Improve Practice? |
| Nov 17, 2017 | Eric Huselton | Improving Outcomes After Allogeneic Tranplant: Risk Factors and Treatment of Relapsed AML |
| Dec 1, 2017 | Ramzi Abboud Brett Herzog | JAK/STAT Pathways and Immunomodulation After Hematopoietic Cell Transplantation and Other Immune Therapies Clonal Dynamics of Non-Small Cell Lung Cancer |
| Dec 15, 2017 | Doug Adkins | Current Clinical Investigations in Head and Neck Cancer at Washington University |
| Dec 22, 2017 | Vivek Arora | Emerging Concepts in Bladder Cancer Management |
| Jan 5, 2018 | Brian Van Tine | Sarcoma Metabolism |
| Jan 12, 2018 | Neha Mehta-Shah | T-Cell Lymphomas: Where We Are and Where We Hope to Be |
| Jan 19, 2018 | Brigitte C. Widemann, MD Pediatric Oncology Branch, NCI | Development of Effective Therapies for NF1 Related Peripheral Nerve Sheath Tumors |
| Jan 26, 2018 | Daniel Guy Amber Xu | Age-Related Clonal Hematopoiesis Past, Present and Future of PARP Inhibition |
| Feb 2, 2018 | Lawrence Einhorn, MD Indiana University | Testicular Cancer: Past History, Present Results and Future Perspectives |
| Feb 9, 2018 | Bruna Pellini Ferreira Nkiruka Ezenwajiaku | Cell Tumor DNA in the Diagnosis and Follow-Up of NSCLC Mixed Phenotype Acute Leukemia |
| Feb 16, 2018 | John P. Leonard, MD Weill Cornell Medical College | New Developments in Lymphoma: Progress and Problems in Precision Therapy |
| Feb 23, 2018 | David T. Curiel, MD, PhD Radiation Oncology | Molecular Engineering of Adenovirus to Actualize Cancer Vaccines |
| Mar 2, 2018 | Thomas M. Maddox, MD, MSc Cardiovascular Division | The Health Systems Innovation Lab: Opportunities to Think Differently About Cancer Care |
| Mar 9, 2018 | Monte Meier Winslow, PhD Stanford University | Molecular Determinants of Lung Cancer Growth and Metastasis |
| Mar 16, 2018 | Daniel Guy Aabha Oza | Prevention of CMV Infection in Patients Undergoing HSCT Progressive Multifocal Leukoencephaolpathy |
| Mar 30, 2018 | Russell W. Jenkins, MD, PhD Dana-Farber/Harvard Cancer Center | Ex-Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids: Developing a Functional Precision Medicine Platform for Immuno-Oncology |
| Apr 6, 2018 | Ramon Jin Patrick Grierson | Metaplasia: The Calm Before the Storm? Targeting the MAPK Pathway in Solid Tumors |
| Apr 13, 2018 | Lee Ratner | Pathogenesis and Treatment of Human T-Cell Leukemia Virus Associated Malignancy |
| Apr 20, 2018 | John DiPersio | Therapeutic Targeting of Hematologic Malignancies |
| Apr 27, 2018 | Jeff Ward | Remodeling of Intratumoral Myeloid and Lymphoid Compartments Following Immune Checkpoint Blockade Therapy |
| May 18, 2018 | Jeffrey A. Moscow, MD Cancer Therapy Evaluation Program, NCI | Precision Cancer Medicine and the NCI’s Experimental Therapeutics Clinical Trials Network (ETCTN) |
| May 25, 2018 | Russell Pachynski | Chemerin in Cancer |
| Jun 8, 2018 | Matthew A. Ciorba, MD Gastroenterology Division | Save IDO Inhibitors! A Role for Tryptophan Metabolism in Colon Cancer |
| Jun 15, 2018 | Francesca Ferraro Amber Afzal | From MGUS to MGCS: When the “Uncertain” Turns to “Ugly” BCL2 Inhibition in Myeloid Malignancies |
| Jun 22, 2018 | Gad Getz, PhD Harvard Medical School | Studying Response and Resistance to Therapy in Cancer |
| Jun 29, 2018 | Pasi A. Jänne, MD, PhD Harvard Medical School | New Therapeutic Stratgies for EGFR Mutant Lung Cancer |
| Date | Speaker | Title |
|---|---|---|
| Jul 15, 2016 | Doug Adkins | INTRODUCTION TO CANCER MANAGEMENT Writing Chemo Orders: The Basics I Must Know and Implement |
| Jul 2, 2016 | Janelle Mann Staff Pharmacist, Medical Oncology | INTRODUCTION TO CANCER MANAGEMENT The Ins and Outs of Anti-Emetics |
| Jul 29, 2016 | Cynthia Ma | INTRODUCTION TO CANCER MANAGEMENT Metastatic Hormone Positive Breast Cancer |
| Aug 5, 2016 | Daniel Morgensztern | INTRODUCTION TO CANCER MANAGEMENT Non-Small Cell Lung Cancer |
| Aug 12, 2016 | Tanya Wildes | INTRODUCTION TO CANCER MANAGEMENT Head and Neck Cancer |
| Aug 19, 2016 | William D. Tap, MD Memorial Sloan Kettering Cancer Center, New York, NY | The Pit and the Pendulum, Emerging Therapies in Soft Tissue Sarcoma |
| Aug 26, 2016 | Nancy Bartlett | INTRODUCTION TO CANCER MANAGEMENT Hodgkin Lymphoma |
| Sep 2, 2016 | Nancy Bartlett | Targeted Approaches to Diffuse Large B Cell Lymphoma |
| Sep 9, 2016 | Timothy Ley | Acute Myeloid Leukemia |
| Sep 16, 2016 | Todd Fehniger | Natural Killer Cell Immunotherapy: Prime or Recollect? |
| Sep 23, 2016 | Gloria M. Petersen, PhD Mayo Clinic College of Medicine, Rochester, MN | LORI GROETKEN MEMORIAL LECTURE Genetic Susceptibility to Pancreatic Cancer: New Insights |
| Sep 30, 2016 | Todd Druley Pediatric Hematology/Oncology | Leukemia-associated Clonal Hematopoiesis Is a Ubiquitous Process in Normal Aging |
| Oct 7, 2016 | Cynthia Ma | CDK 4/6 in ER+ Breast Cancer |
| Oct 14, 2016 | Lingling Du Hematology-Oncology Fellow | IDO Inhibition in Cancer Treatment |
| Oct 21, 2016 | Gideon M. Blumenthal, MD Center for Drug Evaluation and Research, FDA, Bethesda, MD | Clinical Trials and Drug Development in Oncology: FDA’s Perspective |
| Oct 28, 2016 | Katherine Weilbaecher | Targeting Dormant and Growing Bone Metastases |
| Nov 4, 2016 | Craig Lockhart | Strategic Targeting of Esophageal Cancers: 2016 Update |
| Nov 11, 2016 | Bita Fakhri Hematology-Oncology Fellow Amber Xu Hematology-Oncology Fellow | Livin’ on a Prayer: Double and Triple Hit Lymphomas Paraneoplastic Opsoclonus-Myoclonus Syndrome |
| Nov 18, 2016 | Sana Saif Ur Rehman Hematology-Oncology Fellow | Chronic Neutrophilic Leukemia: Novel Mutations and Impact on Clinical Practice |
| Dec 9, 2016 | Tom Regenbogen Hematology-Oncology Fellow | Non-Surgical Liver Directed Therapy |
| Dec 16, 2016 | Mark Watson Laboratory & Genomic Medicine | Detection of Rare Tumor Cells |
| Jan 6, 2017 | Scott Kopetz, MD, PhD MD Anderson Cancer Center, Houston, TX | Targeting BRAF in Colorectal Cancer |
| Jan 20, 2017 | Francesca Ferraro Hematology-Oncology Fellow Eric Huselton Hematology-Oncology Fellow | Hypomethylating Agents in Acute Myeloid Leukemia BCL-2 Inhibition in CLL |
| Jan 27, 2017 | Marcel van den Brink, MD, PhD Memorial Sloan Kettering Cancer Center, New York, NY | Strategies to Enhance Hematopoietic Stem Cell Transplantation |
| Feb 3, 2017 | Sid Devarakonda Hematology-Oncology Fellow | Origins and Genomic Landscape of Small Cell Lung Cance |
| Feb 10, 2017 | Sam Achilefu Radiology | Light Mediated Molecular Imaging and Treatment of Cancer |
| Feb 17, 2017 | Maria-Grazia Roncarolo, MD Stanford University, Stanford, CA | T Regulatory Cells in Immunomediated Diseases: From Bench to Bedside and Beyond |
| Feb 24, 2017 | Richard Wahl Radiology | Quantitative Imaging to Phenotype Patients With Cancer |
| Mar 3, 2017 | Deborah Schrag, MD, MPH Dana-Farber Cancer Institute, Boston, MA | Pilots to Populations: Quality, Efficacy and Effectiveness of Rectal Cancer Treatment |
| Mar 10, 2017 | Andy Liao Hematology-Oncology Fellow | Emerging Treatment Options in Cholangiocarcinoma |
| Mar 17, 2017 | Amanda Cashen | CAR T-Cells: How Will We Weigh the Risks and Benefits? |
| Mar 24, 2017 | Ezra Cohen, MD UC San Diego, La Jolla, CA | Immune Approaches in Head and Neck Cancer |
| Mar 31, 2017 | Natasha Edwin Hematology-Oncology Fellow Patrick Grierson Hematology-Oncology Fellow | Burnout Among Oncologists Immunotherapy in GI Malignancies |
| Apr 7, 2017 | Aabha Oza Hematology-Oncology Fellow Stephen Barman Hematology-Oncology Fellow | Peritoneal Carcinomatosis: Intraperitoneal Chemotherapy and Cytoreductive Surgery Urothelial Carcinoma: Review and Updates of Second-Line Treatment |
| Apr 14, 2017 | Goutham Narla, MD, PhD Case Western Reserve University, Cleveland, OH | Novel Therapies to Activate Tumor Suppressor Proteins for Cancer Treatment |
| Apr 21, 2017 | Kwok-Kin Wong, MD, PhD NYU Langone Medical Center, New York, NY | The Use of Mouse Lung Cancer Models for Preclinical Testing of Novel Targeted and Immune Therapies |
| Apr 28, 2017 | Vassiliki Saloura, MD University of Chicago | WHSC1L1 as an Oncogenic Methyltransferase in Head and Neck Cancer: Progress Towards Clinical Translation |
| May 5, 2017 | Tanya Wildes | Age Is Just a Surrogate for Aging: Weaving the Principals of Geriatrics Into the Fabric of Oncology |
| May 12, 2017 | Tanner Johanns Hematology-Oncology Fellow | hTERT as an Immunologic Target |
| May 19, 2017 | Nusayba Bagegni Hematology-Oncology Fellow Francesca Ferraro Hematology-Oncology Fellow | Management of Leptomeningeal Disease Secondary ALL (Acute Lymphoblastic Leukemia): A Real Entity? |
| May 26, 2017 | Nkiruka Ezenwajiaku Hematology-Oncology Fellow Amber Afzal Hematology-Oncology Fellow | Hepatic Veno-Occlusive Disease Outcomes of Stem Cell Transplant in Myelofibrosis |
| Jun 9, 2017 | Patrick Grierson Hematology-Oncology Fellow Pavan Bhamidipati Hematology-Oncology Fellow | NK Cell Lymphoma IDH Mutations in AML and Novel Therapeutics |
| Jun 16, 2017 | Chris Maher | The Biological and Clinical Significance of Long Non-Coding RNAs |
| Jun 23, 2017 | Matt Walter | Genomics of Myelodysplastic Syndromes |
| Jun 30, 2017 | F. Stephen Hodi, MD Dana-Farber Cancer Institute, Boston, MA | Combinatorial Approaches With Immune Checkpoint Blockade to Treat Cancer |